Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of Canada and the US, to focus on improving the health of women throughout their lives. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

In June 2021, Organon appointed Julio Cesar Conejero as General Manager in Latin America, Juan Patricio Clark as Business Director in Colombia and Fernando Fogarin, Executive Director in Mexico.

Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately US$6.5 billion in annual revenue generated outside the US.

The company has three core pillars that will benefit from renewed management focus and commercial investment: women’s health, biosimilars and established brands.

Biosimilars are a key growth pillar with products available in various parts of the world, such as infliximab and etanercept in immunology and trastuzumab in oncology. Organon’s expertise is in the commercialization of these products, allowing their accessibility to more people worldwide.

Related articles
Biobadamérica promotes the use of biological and biosimilar drugs in Latin America

PlantForm and partners in Brazil to develop pembrolizumab biosimilar

  
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.